Search

Displaying results 891 - 900 of 5089 in total
  1. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  2. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

  3. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development

  4. Drug

    Benzydamine

    go.drugbank.com/drugs/DB09084
    ApprovedInvestigational

    Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain reli...

    Mixtures: TANTUM VERDE DUO 22,5 MG+18 MG/15 ML GARGARA, TANTUM VERDE DUO FORTE 0,30 / %0,12 ORAL SPREY, ÇÖZELTİProducts: Nu-benzydamine Oral Rinse, BENZIRIN® ROSA DUCHA LISTA PARA SU USO
  5. Drug

    Alvimopan

    go.drugbank.com/drugs/DB06274
    ApprovedInvestigational

    Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.

    Categories: Receptors, Opioid, mu, antagonists & inhibitors
  6. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of ...

  7. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 b...

  8. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary

  9. Drug

    Sodium lauryl sulfate

    go.drugbank.com/drugs/DB00815
    Approved

    Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consists of a mixture of sodium alkyl sulfates, mainly the lauryl.

    Mixtures: Medi Hydro DP Cleanser
  10. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome … [A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD

    Products: ROVARIL® 10 MG CAPSULAS BLANDAS DE GELATINA